SummaryRMgm-5355
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene tagging, Introduction of a transgene |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 37883438 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 507cl1 (RMgm-7) |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Baily AJ, Vlachou D |
Name Group/Department | Department of Life Sciences |
Name Institute | Imperial College London |
City | London |
Country | UK |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5355 |
Principal name | aqp2::3xha |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Western blot analysis of aqp2::3xha parasite protein extracts using an antibody against the HA epitope showed the expected ca. 73 kDa protein predominantly in gametocytes – already prior to gametogenesis activation and, at a lower abundance, in mature ookinetes. In indirect immunofluorescence assays of aqp2::3xha parasites, AQP2::3xHA was seen to specifically localize to vesicle-like structures in the cytoplasm of gametocytes, ookinetes and midgut sporozoites. The number and appearance of these structures varied from 1-2 large spots and several smaller ones in gametocytes, 2-3 and occasionally 1-4 spots in ookinetes, and 2-3 spots in sporozoites. |
Fertilization and ookinete | Western blot analysis of aqp2::3xha parasite protein extracts using an antibody against the HA epitope showed the expected ca. 73 kDa protein predominantly in gametocytes – already prior to gametogenesis activation and, at a lower abundance, in mature ookinetes. In indirect immunofluorescence assays of aqp2::3xha parasites, AQP2::3xHA was seen to specifically localize to vesicle-like structures in the cytoplasm of gametocytes, ookinetes and midgut sporozoites. The number and appearance of these structures varied from 1-2 large spots and several smaller ones in gametocytes, 2-3 and occasionally 1-4 spots in ookinetes, and 2-3 spots in sporozoites. In ookinetes, this pattern resembles that of crystalloid, an elusive organelle exclusive to ookinetes and young oocysts. Although these spots were often seen adjacent to the hemozoin crystals, the waste product of hemoglobin metabolism and hallmark of the ABS food vacuole and the crystalloid, they never fully colocalized with the hemozoin or located amongst the hemozoin crystals where the crystalloid is found. Indeed, the diameter of these structures in ookinetes (0.2-0.7 μm) was smaller than that of crystalloids (0.3-1.15 μm) as determined by IFAs of the recently identified crystalloid proteins CRYSP and CRONE. The diameter of these structures was more uniform in all sporozoites examined (0.25-0.4 μm). |
Oocyst | Not tested |
Sporozoite | In indirect immunofluorescence assays of aqp2::3xha parasites, AQP2::3xHA was seen to specifically localize to vesicle-like structures in the cytoplasm of gametocytes, ookinetes and midgut sporozoites. The number and appearance of these structures varied from 1-2 large spots and several smaller ones in gametocytes, 2-3 and occasionally 1-4 spots in ookinetes, and 2-3 spots in sporozoites. In ookinetes, this pattern resembles that of crystalloid, an elusive organelle exclusive to ookinetes and young oocysts. Although these spots were often seen adjacent to the hemozoin crystals, the waste product of hemoglobin metabolism and hallmark of the ABS food vacuole and the crystalloid, they never fully colocalized with the hemozoin or located amongst the hemozoin crystals where the crystalloid is found. Indeed, the diameter of these structures in ookinetes (0.2-0.7 μm) was smaller than that of crystalloids (0.3-1.15 μm) as determined by IFAs of the recently identified crystalloid proteins CRYSP and CRONE. The diameter of these structures was more uniform in all sporozoites examined (0.25-0.4 μm). |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Protein (function) From the paper: Phenotype Western blot analysis of aqp2::3xha parasite protein extracts using an antibody against the HA epitope showed the expected ca. 73 kDa protein predominantly in gametocytes – already prior to gametogenesis activation and, at a lower abundance, in mature ookinetes. Additional information |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1427100 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0810400 | ||||||||||||||||||||||||||
Gene product | aquaporin, putative | ||||||||||||||||||||||||||
Gene product: Alternative name | aquaporin 2, AQP2 | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Name of the tag | triple-HA | ||||||||||||||||||||||||||
Details of tagging | C-terminal | ||||||||||||||||||||||||||
Additional remarks: tagging | |||||||||||||||||||||||||||
Commercial source of tag-antibodies | |||||||||||||||||||||||||||
Type of plasmid/construct | (Linear) PCR construct double cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | Yes | ||||||||||||||||||||||||||
Name of PlasmoGEM construct/vector | - | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | Generation of P. berghei Δpbaqp2 and pbaqp2::3xha: We used the PlasmoGEM vectors PbGEM_321755 and PbGEM-066039 for PbAQP2 disruption and C-terminal 3xHA tagging, respectively. These vectors contain the human DHFR (hDHFR) selection cassette that confers resistance to pyrimethamine and the negative selection cassette yFCU that substitutes the delivery of 5-fluorocytosine. The targeting cassettes were released by NotI digestion resulting in 74% deletion of PbAQP2 coding sequence at the gene 5′ end. | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | GFP (gfp-mu3) | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | gfp (FACS) | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | FACS (flowsorting) | ||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||
Additional remarks genetic modification | The GFP gene (1 copy) has been inserted into the 230p locus (PBANKA_030600) by double cross-over integration. | ||||||||||||||||||
Additional remarks selection procedure | This reporter mutant expressing GFP does not contain a drug-selectable marker. This mutant has been selected by FACS sorting after transfection based on GFP fluorescence | ||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1133300 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1357100 | ||||||||||||||||||
Gene product | elongation factor 1-alpha | ||||||||||||||||||
Gene product: Alternative name | eef1a | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0719300 | ||||||||||||||||||
Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative | ||||||||||||||||||
Gene product: Alternative name | dhfr/ts | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_0306000 | ||||||||||||||||||
Gene product | 6-cysteine protein | ||||||||||||||||||
Gene product: Alternative name | 230p | ||||||||||||||||||
| |||||||||||||||||||
top of page |